

# Magellan Compliance Notebook – May, 2017

Magellan Behavioral Health of Pennsylvania, Inc. (Magellan) strives to be proactive and use education as a preventative tool to help ensure our members receive the highest quality of care through you, the provider. The Compliance Department at Magellan is committed to sending monthly e-mails to targeted providers regarding a Compliance-related subject.

*This e-mail communication is specific to your HealthChoices (Pennsylvania Medicaid) Contract with Magellan.*

This month we've elected to share a March, 2017 communication from DHS to ensure that providers are aware of the coverage responsibility for Medication Assisted Treatment Services (MAT) for Individuals with Opiate Use Disorder (OUD).

---

Behavioral Health Managed Care Organizations (BH MCOs) including Magellan and Physical Health Managed Care Organizations (PH MCOs) are responsible for coverage of medication assisted treatment involving buprenorphine and injectable naltrexone within their respective networks as delineated below.

When a behavioral health provider prescribes buprenorphine or injectable naltrexone, the PH-MCO is responsible for coverage of and payment for the prescribed medication. The BH-MCO is not responsible for the payment of these prescriptions. The BH-MCO is responsible for coverage of and payment for related medication assisted treatment services such as evaluation and management assessments, medication assessments, diagnostic tests, laboratory screening tests, injection fees and any other medically necessary services rendered by the behavioral health provider. To prescribe buprenorphine products for medication assisted treatment, the behavioral health provider must be enrolled in the MA program, participate as an in-network provider and be granted a waiver from SAMHSA to prescribe buprenorphine products. Providers prescribing injectable naltrexone must meet the same requirements except for the SAMHSA waiver. The BH-MCO is responsible to pay for drug and alcohol counseling services offered by BH-MCO enrolled providers to persons receiving buprenorphine products and injectable naltrexone. BH health prescribers of buprenorphine products and injectable naltrexone must coordinate their treatment services with the patient's primary care provider and other appropriate substance use disorder treatment providers.

When a physical health provider prescribes buprenorphine or injectable naltrexone, the PH-MCO is responsible for coverage of and payment for the medication as well as related treatment services such as evaluation and management assessments, diagnostic tests,

laboratory screening tests, injection fees and any other medically necessary services rendered by the physical health provider.

---

At Magellan, we will continue to educate our providers with updated MA Bulletins, Regulations and other pertinent information in order to ensure Compliance.

Thank you for your ongoing hard work and dedication to our members!

## Magellan of Pennsylvania's Compliance Team

☎ 215-504-3967 | 📠 866-667-7744

[www.magellanofpa.com](http://www.magellanofpa.com)

Report Fraud to: [SIU@magellanhealth.com](mailto:SIU@magellanhealth.com) or (800) 755-0850



**Magellan**  
HEALTHCARE

